Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway (INNOVA-LUNG)
Impatto Della Biopsia Liquida Sul Percorso Terapeutico Del Tumore al Polmone: Anticipare la Caratterizzazione Molecolare Dei Pazienti Con Adenocarcinoma Del Polmone in Stadio Avanzato Integrando la Biopsia Liquida Nella Fase Iniziale Del Percorso Diagnostico-terapeutico
This multicenter pilot observational study aims to assess the feasibility of introducing liquid biopsy at an early stage of the diagnostic pathway for patients with suspected advanced non-small cell lung cancer (NSCLC).
Liquid biopsy is a minimally invasive blood test that can detect tumor-related genetic alterations in circulating nucleic acids. The study will evaluate whether this approach can provide molecular information more rapidly than standard tissue-based testing and how closely the results obtained from blood samples match those obtained from tumor tissue.
Approximately 70 adult patients with radiological evidence of locally advanced or metastatic lung cancer will be enrolled. Participants will undergo a blood draw for liquid biopsy and will continue to follow the standard diagnostic pathway, including tissue biopsy or cytological sampling when indicated.
The results generated within the study are intended for research purposes and will not replace standard diagnostic procedures or independently determine treatment decisions. The findings will be used to identify practical and methodological issues and to support the design of future clinical studies on the plasma-first approach.
調査の概要
詳細な説明
Molecular characterization is an essential step in the management of advanced non-small cell lung cancer (NSCLC), as the identification of actionable genomic alterations may guide the selection of targeted therapies. However, tissue-based molecular testing may be delayed or limited by insufficient or poor-quality biological material.
Liquid biopsy allows the analysis of circulating tumor-derived nucleic acids from a peripheral blood sample and may provide molecular information earlier in the diagnostic pathway. The plasma-first approach consists of performing liquid biopsy at an early stage, while the patient continues the standard diagnostic process.
This is a multicenter, prospective, non-pharmacological pilot observational study involving adult patients with radiological suspicion of locally advanced NSCLC not suitable for locoregional treatment or metastatic NSCLC. Eligible patients must have a tissue biopsy or cytological sampling planned but not yet performed, or already performed without an available histopathological diagnosis of NSCLC at the time of enrollment.
Each participant will undergo a peripheral blood draw for liquid biopsy within one week of the first clinical assessment. Plasma-derived circulating nucleic acids will be analyzed using next-generation sequencing (NGS). Participants will then continue the standard diagnostic pathway of the enrolling center, including tissue biopsy or cytological sampling, histopathological diagnosis, PD-L1 assessment, and standard tissue-based molecular profiling.
The study will assess the feasibility of the plasma-first approach and will generate a structured dataset to support the design of future prospective studies. Secondary objectives include evaluating:
- the turnaround time of plasma-based and tissue-based molecular testing;
- the proportion of informative liquid biopsy results;
- the concordance between molecular alterations detected in plasma and tissue samples;
- the performance of different NGS-based approaches for the detection of genomic alterations;
- the tumor fraction in plasma samples and its relationship with molecular and clinical variables;
- the potential organizational and economic implications of integrating liquid biopsy into the diagnostic pathway.
For participants enrolled at the coordinating center, additional exploratory analyses will be performed to estimate tumor fraction and compare two NGS-based analytical approaches.
The results of the liquid biopsy performed within this pilot study are collected for research purposes. They will not replace standard diagnostic procedures and will not independently determine the initiation of treatment. Treatment decisions will remain based on the standard diagnostic and clinical assessment performed according to current clinical practice.
The study plans to enroll approximately 70 participants over a 6-month recruitment period, with an observation period of 12 months and an overall estimated study duration of 18 months.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Maristella Giammaruco, MD
- 電話番号:+39 06 5266 5698
- メール:maristella.giammaruco@ifo.it
研究連絡先のバックアップ
- 名前:Simonetta Buglioni, Biology
研究場所
-
-
RM
-
Roma、RM、イタリア、00144
- 募集
- IFO-IRE, Istituto Nazionale Tumori Regina Elena
-
主任研究者:
- Federico Cappuzzo, MD
-
コンタクト:
- Maristella Giammaruco, MD
- 電話番号:+39 06 5266 5698
- メール:maristella.giammaruco@ifo.it
-
コンタクト:
- Simonetta Buglioni, Biology
- 電話番号:+39 06 5266 2923
- メール:simonetta.buglioni@ifo.it
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Age ≥ 18 years.
- Radiological suspicion of locally advanced lung cancer not amenable to locoregional treatment or metastatic lung cancer (stage III-IV).
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
- Tissue biopsy and/or cytological sampling planned but not yet performed, or already performed without an available histopathological diagnosis of non-small cell lung cancer (NSCLC).
- Written informed consent for study participation and personal data processing obtained before any study-specific procedure.
Exclusion Criteria:
- Previous or current history of non-small cell lung cancer (NSCLC).
- Histopathological diagnosis of NSCLC already available following tissue biopsy.
- Eligibility for surgical removal of tumor tissue.
- Ongoing or previous systemic oncological treatment for lung cancer.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Prospective Plasma-First NSCLC Cohort
Adult patients with radiological suspicion of locally advanced non-small cell lung cancer (NSCLC) not suitable for locoregional treatment, or metastatic NSCLC, will be enrolled before completion of the standard diagnostic pathway. Participants will undergo a peripheral blood draw for liquid biopsy within one week of the first clinical assessment. Plasma-derived circulating nucleic acids will be analyzed using next-generation sequencing (NGS) to evaluate molecular alterations, turnaround time, concordance with tissue-based profiling, and tumor fraction. All participants will continue the standard diagnostic pathway of the enrolling center, including tissue biopsy or cytological sampling, histopathological diagnosis, PD-L1 assessment, and tissue-based molecular testing. No investigational treatment is assigned, and study procedures will not independently determine treatment decisions. |
Participants will undergo a peripheral blood draw for plasma-based liquid biopsy within one week of the first clinical assessment. Circulating cell-free nucleic acids extracted from plasma will be analyzed using next-generation sequencing (NGS) to identify molecular alterations and evaluate turnaround time, concordance with tissue-based molecular profiling, and tumor fraction. The liquid biopsy is performed for research purposes within this pilot observational study. Participants will continue the standard diagnostic pathway of the enrolling center, including tissue biopsy or cytological sampling, histopathological diagnosis, PD-L1 assessment, and standard tissue-based molecular testing. The study procedure will not independently determine treatment decisions. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Feasibility of establishing a structured plasma-first molecular profiling dataset
時間枠:Up to 18 months
|
Proportion of enrolled participants with a complete structured dataset including liquid biopsy results, tissue-based diagnostic and molecular profiling results, and relevant clinical data required for the feasibility assessment of the plasma-first approach.
|
Up to 18 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Turnaround time for plasma-based molecular profiling
時間枠:Up to 7 days from blood collection
|
Time in days from peripheral blood collection to availability of the liquid biopsy molecular profiling report.
|
Up to 7 days from blood collection
|
|
Proportion of participants with informative liquid biopsy results
時間枠:Up to 30 days from enrollment
|
Proportion of enrolled participants in whom plasma-based molecular profiling identifies at least one clinically actionable genomic alteration with established evidence supporting targeted therapy.
|
Up to 30 days from enrollment
|
|
Concordance between plasma-based and tissue-based molecular profiling
時間枠:Up to 30 days from enrollment
|
Proportion of participants with concordant molecular profiling results between plasma-derived circulating nucleic acids and matched tissue or cytological samples.
|
Up to 30 days from enrollment
|
|
Tumor fraction in plasma samples
時間枠:Up to 30 days from blood collection
|
Distribution of estimated tumor fraction values in plasma samples and proportion of samples with sufficient circulating tumor DNA concentration for molecular analysis.
|
Up to 30 days from blood collection
|
|
Analytical performance of two NGS-based plasma profiling approaches
時間枠:Up to 18 months
|
Comparison of the ability of amplicon-based and hybrid-capture next-generation sequencing approaches to detect genomic alterations, including low variant allele frequency alterations and gene fusions, in plasma-derived circulating nucleic acids.
|
Up to 18 months
|
協力者と研究者
捜査官
- 主任研究者:Federico Cappuzzo, MD、IFO-IRE, Istituto Nazionale Tumori Regina Elena
出版物と役立つリンク
一般刊行物
- Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, Leighl N, Malapelle U, Mok T, Peled N, Raez LE, Sequist L, Sholl L, Swanton C, Abbosh C, Tan D, Wakelee H, Wistuba I, Bunn R, Freeman-Daily J, Wynes M, Belani C, Mitsudomi T, Gandara D. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021 Oct;16(10):1647-1662. doi: 10.1016/j.jtho.2021.06.017. Epub 2021 Jul 8.
- Low SK, Ariyasu R, Uchibori K, Hayashi R, Chan HT, Chin YM, Akita T, Harutani Y, Kiritani A, Tsugitomi R, Manabe R, Ogusu S, Amino Y, Kitazono S, Yanagitani N, Nakamura Y, Nishio M. Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus integrated sequencer. Transl Lung Cancer Res. 2022 May;11(5):711-721. doi: 10.21037/tlcr-21-981.
- Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, Parachoniak CA, McLaughlin-Drubin M, Erlich RL, Schrock AB, Frampton GM, Das Thakur M, Oxnard GR, Tukachinsky H. Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples. JCO Precis Oncol. 2022 Oct;6:e2200261. doi: 10.1200/PO.22.00261.
- Garcia-Pardo M, Czarnecka K, Law JH, Salvarrey A, Fernandes R, Fan J, Corke L, Waddell TK, Yasufuku K, Donahoe LL, Pierre A, Le LW, Ghumman N, Liu G, Shepherd FA, Bradbury P, Sacher A, Stockley T, Pal P, Rogalla P, Tsao MS, Leighl NB. Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy. Ther Adv Med Oncol. 2022 Sep 20;14:17588359221126151. doi: 10.1177/17588359221126151. eCollection 2022.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- RS348/2025
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。